Alder BioPharmaceuticals Announces Closing of $250M of 2.50% Convertible Senior Notes Due 2025 Post author:Sam Post published:February 1, 2018 Post category:BioPharma Alder intends to use the cash to fund the development and commercialization of eptinezumab. Source: BioSpace You Might Also Like SanBio, Inc. Receives $20 Million Grant From For Stroke Clinical Trial July 4, 2017 Radius Health's Longtime CEO Out, Former Novo Nordisk A/S Exec Named New Leader July 16, 2017 How Alexion is Making So Much Cash With a Drug That Treats Less Than 11,000 Patients May 23, 2017